Coegin Pharma AB listed on Nordic SME
Sarsia Seed portfolio company Coegin Pharma AB was yesterday listed on Nordic SME stock exchange. (Ticker: COEGIN) Read more
les merVaccibody AS Lists on Oslo Stock Exchange
Sarsia Seed portfolio company Vaccibody AS - was today listed on Oslo Stock Exchange´s Merkur Markets list. ...
les merVaccibody enters into worldwide license and collaboration agreement with Genentech
It was announced today that Sarsia Seed portfolio company Vaccibody AS enters into $715m lisence and collaboration agreement with Genentech.Low double-digit tiered royalties on sales of commercialized products arising from the partnership are in addition. ...
les merVaccibody and Nektar Therapeutics Announce First Patient Dosed in collaborative Phase 1/2a Study
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's...
les merVaccibody doses first patient in Phase II clinical trial of VB10.16 in combination with immune-checkpoint inhibitor in advanced cervical cancer
Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...
les merRallybio raises USD 145 mill to develop asset acquired from Prophylix Pharma
US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company's portfolio of product candidates targeting devastating rare diseases. Rallybio's lead candidate is RLYB211 that the company acquired...
les merBerGenBio raises Euro 45 million in over subscribed private placement
BerGenBio today announced that the company has raised mNOK via a private placement that took place via an accelerated book building process after close of market on 4 May 2020. Read more
les merBerGenBio’s Bemcentinib selected to be fasttracked as potential treatment for COVID-19
BerGenBio announces that bemcentinib has been selected to be fast-tracked in a new UK national multi-centre randomised Phase 2 clinicial trial initiative that aims to get an early indication of whether bemcentinib could save lives and improve outcomes in the most...
les merVaccibody listed on NOTC
Vaccibody AS announces that it will register on the Norwegian OTC-list (“NOTC”), owned and operated by Oslo Børs, from January 27. Vaccibody will trade under the ticker “VACC”. Read more
les merVaccibody announces positive clinical trial results
Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine. The data is from the first 16 patients assessed for safety after treatment with a VB10.NEO, and the first 14 patients...
les mer